We are pleased to announce big changes in access to COVID-19 vaccinations for people living with ALS in Illinois. The State is making plans to expand COVID-19 Phase 1B vaccination eligibility on February 25 to people who have comorbidities and …
ALS Groups Urge Social Security Administration to Grant Immediate Access to SSDI Benefits
The Les Turner ALS Foundation has joined with 18 other ALS advocacy organizations, signing onto a letter strongly urging the Social Security Administration to honor the enactment for all those already in the waiting period. On December 22, 2020, the …
Foundation Advocating for COVID-19 Vaccination Prioritization for Individuals with ALS
As we turn the calendar to 2021, the Les Turner ALS Foundation is taking proactive steps to help ensure that those living with neuromuscular disease, including ALS, are given priority access to COVID-19 vaccines and treatments. On Wednesday, January 6, Illinois …
Research May Lead to New Ways to Combat ALS
Because we live in a changing environment, our survival and function depend on adapting to novel, potentially stressful, conditions. Is our ability to adapt to changing conditions fixed or is it possible to enhance our ability to tolerate a stressful …
Global Connections to Create a World Free of ALS
Andrea Pauls Backman, CEO, and member of the Board of Directors of the International Alliance of ALS/MND Associations Every December for the last 31 years, the ALS/MND community has gathered in various locations across the globe to share new findings …
ALS Disability Insurance Access Act Signed into Law
We are excited to announce that on Tuesday (December 22), the ALS Disability Insurance Access Act (H.R. 1407/S. 578) was signed into law, ending the five-month waiting period for people with ALS to access Social Security Disability Insurance benefits. The …
Caring for Our Caregivers
“Caregivers have insights to help others deal with the isolation, uncertainties, and fear during this pandemic because we face similar challenges in our caregiving roles,” says Jan Herwaldt of Sugar Grove. “I have heard it said, ‘we are all in …
Statement from Novartis Gene Therapies: OAV301 program for familial ALS caused by SOD1 mutation
Please see summary below from Novartis Gene Therapies on the OAV301 program for familial ALS caused by the SOD1 mutation: Novartis Gene Therapies (formerly AveXis) deeply appreciates the collaboration and support of the amyotrophic lateral sclerosis (ALS) community. Our ALS …
BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study
Today was a tough call for the ALS community, but not entirely disheartening. BrainStorm released the topline results this morning (November 17) from its Phase 3 trial for NurOwn® showing it did not meet statistical significance in its primary efficacy …
Amylyx Publishes CENTAUR Survival Data Demonstrating Statistically Significant Survival Benefit of AMX0035 for People with ALS
We are excited to share some promising data regarding the CENTAUR trial evaluating AMX0035 in people with ALS on overall survival analysis, published today (October 16, 2020) in the neuromuscular disease journal Muscle & Nerve. The survival analysis followed each …
